Recipharm has announced the launch of its standalone serialization service ahead of the introduction of the EU Falsified Medicines Directive (FMD). The new service is designed to offer pharmaceutical companies access to Recipharm’s serialization capabilities as a standalone service due to increasing concerns that many will not be ready for the February 2019 compliance deadline. Moving forward, Recipharm will be able to add 2D codes, human readable text and tamper evidence to pre-packed me...